Ishita Drugs & Industries Ltd (ISHITADR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Ishita Drugs & Industries Ltd on NSE and BSE, with an AI summary of each filing.
Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 alongwith limited review report issued by the statutory auditors of the Company.
Financial Result · 03 Nov 2026, 10:57 pm
Ishita Drugs Reports Q2 Results And Progresses Facility Upgradation Ishita Drugs and Industries reported revenue from operations of Rs. 303.31 lakh for the quarter ended 30th Sep'26, down from Rs. 314.53 lakh in Q1 and Rs. 306.81 lakh YoY. Net profit stood at Rs. 16.08 lakh versus Rs. 23.02 lakh QoQ and Rs. 14.33 lakh YoY. Basic EPS was Rs. 0.54. Separately, the board reviewed its Schedule M manufacturing facility upgrade; the company spent ~Rs. 488 lakh on civil work and paid Rs. 190 lakh in capex, partly funded via a Rs. 51.90 lakh HDFC Bank loan disbursement.
Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. Tuesday, 03rd November, 2026 have 1. Approved the Unaudited Financial Results of the Company for ....
Outcome · 03 Nov 2026, 10:50 pm
Ishita Drugs & Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 303 (-1.1% YoY | -3.6% QoQ) ■ EBITDA: 16.3 (-12.3% YoY | -48.9% QoQ) ■ EBITDA Margin (%): 5.4 (-69 bps YoY | -476 bps QoQ) ■ PAT: 16.1 (+12.2% YoY | -30.1% QoQ) ■ EPS (INR): 0.54 (+12.5% YoY | -29.9% QoQ)
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve 1. To consider, approve ....
Intimation · 03 Nov 2026, 5:30 am
Ishita Drugs Schedules Board Meeting to Approve Q2 Results Ishita Drugs & Industries Ltd has scheduled a meeting of its Board of Directors on 3rd Nov'26 to consider, approve, and record the company's unaudited financial results for the quarter ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities by designated persons remains closed from 1st Oct'26 until 48 hours following the formal announcement of the quarterly financial results.
1. Approval of re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non Executive Non-Independent Director of the Company post attaining the age of 75 years , and who retires by rotation, ....
Change in Management · 02 Oct 2026, 11:25 pm
Ishita Drugs Approves Director and Statutory Auditor Re-Appointments Ishita Drugs & Industries Limited announced that shareholders at its 33rd AGM on 30th Sep'26 (voting declared 2nd Oct'26) approved the re-appointment of promoter Mrs. Abha Agrawal as a Non-Executive Non-Independent Director post attaining 75 years of age, effective 1st Oct'26. Additionally, shareholders approved the re-appointment of M/s. Jaymin Shah & Associates, Chartered Accountants, as Statutory Auditors for a one-year term from the conclusion of the 33rd AGM until the conclusion of the 34th AGM.
Re-appointment of M/s. Jaymin Shah & Associates, Chartered Accountants (FRN: 129406W) as a statutory Auditor of the Company for the FY 2026-27.
Change in Auditor · 02 Oct 2026, 11:17 pm
Ishita Drugs Re-Appoints Jaymin Shah & Associates as Statutory Auditor Ishita Drugs & Industries has approved the re-appointment of M/s. Jaymin Shah & Associates, Chartered Accountants (FRN: 129406W), as its Statutory Auditors for FY26-27, effective 1st Oct'26. The firm will hold office from the conclusion of the 33rd Annual General Meeting until the conclusion of the 34th Annual General Meeting, on mutually agreed remuneration terms. The signing partner for the audit firm will be Mayank Sancheti (Membership No. 170863).
Disclosure of Voting Results and Scrutinizer''s Report for 33rd Annual General Meeting of the Company held on Wednesday, 30th September, 2026.
Annual General Meeting · 02 Oct 2026, 10:53 pm
Proceedings of the 33rd Annual General Meeting of the Company held on 30th September, 2026 at 11:30 A.M. and concluded on 12:30 P.M.
Annual General Meeting · 30 Sept 2026, 10:20 pm
Pursuant to the Regulation 30read with Schedule III of SEBI(LODR) Regulations, 2015, we wish to inform you that Ishita Drugs and Industries Limited has entred into loan agreement with HDFC ....
Others (Uncategorized) · 22 Sept 2026, 11:21 pm
Ishita Drugs Secures ₹11.75 Cr Credit Facility from HDFC Bank Ishita Drugs and Industries Limited entered into a loan agreement with HDFC Bank Limited on 22nd Sep'26 for credit facilities totaling ₹11.75 Cr. The financing comprises a ₹9.75 Cr term loan to fund facility upgrades at Sanand, Gujarat, to comply with Revised Schedule M norms, alongside a ₹2.00 Cr working capital facility. The credit lines are secured by a first charge on the company’s movable and immovable assets at the Sanand manufacturing site. The transaction is at arm's length with no special governance rights granted.
we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, held its meeting today i.e. Tuesday, 22nd September, 2026, has, Approved the borrowings from the ....
Outcome · 22 Sept 2026, 8:57 pm
Ishita Drugs Board Approves Rs 11.75 Crore Borrowing from HDFC Bank Ishita Drugs and Industries Limited's Board of Directors approved borrowings totaling Rs 11.75 crore from HDFC Bank Limited on 22nd Sep'26. The approved credit facilities comprise a term loan of Rs 9.75 crore and a working capital facility of Rs 2.00 crore, sanctioned under terms outlined in HDFC Bank's letter dated 17th Sep'26. The facility falls within the shareholder-approved limits set during the company's 31st AGM held on 30th Sep'24 under Section 180(1)(c) of the Companies Act, 2013.
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2026 ,inter alia, to consider and approve 1. To consider and ....
Intimation · 18 Sept 2026, 11:49 pm
Ishita Drugs Board to Consider Fund Raising via Loan Facilities Ishita Drugs & Industries Ltd has scheduled a Board of Directors meeting on 22nd Sep'26 to consider and approve raising funds via working capital and project term loan facilities. The board will also review and finalize the terms and conditions associated with these proposed debt financing arrangements.
Company has issued letters providing a weblink of Company''s website to access Annual report for Financial Year 2025-26 to those members who have not registered their email addresses.
Annual Report · 31 Aug 2026, 8:02 pm
Annual Report for the Financial Year 2025-26 including Notice of 33rd Annual General Meeting of the Company to be held on 30.09.2026.
Others (Uncategorized) · 27 Aug 2026, 9:31 pm
Notice of 33RD AGM of the Company which will be held on wednesday, 30th September, 2026 and E voting period for AGM commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (5:00 p.m. IST)
Annual General Meeting · 27 Aug 2026, 9:24 pm
The E-voting period for ensuing 33rd AGM which is to be held on 30.09.2026 will commence from 27.09.2026 (09:00 a.m. IST) and ends on 29.09.2026 (05:00 p.m. IST) (Both days inclusive).
Annual General Meeting · 27 Aug 2026, 9:17 pm
Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as a Non -executive Non- Inependent Director of the Company post attaining the age of 75 years.
Change in Management · 08 Aug 2026, 9:17 pm
Ishita Drugs Reports Q1FY27 Results & Updates on Manufacturing Facility Upgradation Ishita Drugs' board, on 08th Aug'26, approved Q1FY27 results and key proposals. Net profit rose to ₹23.02 lakh, up 29.7% QoQ but down 23.8% YoY. Revenue from operations was ₹314.53 lakh, a 2.9% QoQ increase but a 41.8% YoY decline. Basic EPS stood at ₹0.77. The board also approved the re-appointment of Mrs. Abha Agrawal as a Non-Executive Director. A manufacturing facility upgradation is underway, with ₹435 lakh spent and capital orders of ₹565 lakh placed. The company is negotiating bank financing for this project.
Unaudited Financial Results of the Compmany for the quarter ended 30th June, 2026 along with limited review report issued by statutory auditor.
Financial Result · 08 Aug 2026, 9:13 pm
Ishita Drugs Reports Q1FY27 Results and Updates on Capex Plan Ishita Drugs reported Q1FY27 results with Net Profit at ₹23.02 lakh, up 29.7% QoQ but down 23.8% YoY. Revenue from Operations stood at ₹314.53 lakh, a 2.9% QoQ increase but a 41.7% YoY decline. Basic EPS for the quarter was ₹0.77. The board also noted progress on its manufacturing facility upgradation, having spent ₹435 lakh to date, with further capital orders of ₹565 lakh issued. The company is currently negotiating with banks to finance the project.
Outcome of the Board meeting held on 08th August, 2026.
Outcome · 08 Aug 2026, 9:05 pm
Ishita Drugs & Industries Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lacs) ■ Revenue: 315 (-41.8% YoY | +2.9% QoQ) ■ EBITDA: 31.8 (-8.2% YoY | +237.3% QoQ) ■ EBITDA Margin (%): 10.1 (+370 bps YoY | +703 bps QoQ) ■ PAT: 23.0 (-23.9% YoY | +29.8% QoQ) ■ EPS (INR): 0.77 (-23.8% YoY | +30.5% QoQ)
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve 1. To consider, approve ....
Intimation · 08 Aug 2026, 5:30 am
Ishita Drugs Schedules Board Meeting for Q1 FY27 Results Ishita Drugs & Industries Ltd. (BSE: 524400) will hold a Board of Directors meeting on 08 Aug'26 to consider and approve the Unaudited Financial Results for the quarter ended 30 Jun'26. In accordance with SEBI regulations, the trading window for designated persons has been closed from 01 Jul'26 and will reopen 48 hours after the results are announced. The key agenda item is the approval of the Q1 FY27 financial performance.
Disclosure under regulation 29(2) of SEBI(SAST) Regulations, 2011, received from Ishita Pharmaceuticals, related party of Ishita Drugs and Industries Limited.
Others (Uncategorized) · 24 Jun 2026, 10:03 pm
Related Party Ishita Pharmaceuticals Acquires Additional Stake Ishita Pharmaceuticals, a related party of Ishita Drugs and Industries Ltd., acquired 223 additional equity shares through an open market transaction on 22-Jun'26. This purchase represents 0.01% of the company's total share capital. Following the acquisition, Ishita Pharmaceuticals' total holding in the company has increased from 32,697 shares (1.09% stake) to 32,920 shares, representing a 1.10% stake. The company's equity share capital remains unchanged at Rs. 29,903,000.
Disclosure under regulation 29(2) of SEBI (SAST) Regulations, 2011, received from Ishita Pharmaceuticals, related party of ishita Drugs and Industries Limited.
Others (Uncategorized) · 19 Jun 2026, 10:58 pm
Related Party Acquires Shares in Ishita Drugs & Industries Ishita Pharmaceuticals, a related party of Ishita Drugs and Industries Ltd., acquired 55 equity shares via an open market transaction on 19 Jun '26. The acquisition is nominal, representing 0.00% of the total share capital. Post-transaction, Ishita Pharmaceuticals' holding increased to 32,697 shares, maintaining its stake at 1.09% of the company's total and diluted share capital. The target company's equity share capital remains unchanged at Rs. 29,903,000, comprising 2,990,300 shares of Rs. 10 each.
Audited Financial Results for the quarter and year ended 31st March, 2026
Financial Result · 30 May 2026, 9:37 pm
Ishita Drugs Reports Q4 & FY26 Results, Notes Decline in Revenue and Profit Ishita Drugs & Industries reported Q4 FY26 net profit at ₹17.74 lakhs, a 38.4% YoY decline from ₹28.80 lakhs. Revenue from operations for the quarter fell 33.0% YoY to ₹305.54 lakhs. For the full year ended 31 Mar'26, net profit was ₹77.85 lakhs, down 10.3% YoY from ₹86.81 lakhs. Full-year revenue stood at ₹1,466.02 lakhs, a marginal 2.2% YoY decrease. The board approved the audited financial results on 30 May'26 and noted an unmodified opinion from the statutory auditors.
Outcome of Board Meeting held on 30th May, 2026
Outcome · 30 May 2026, 9:24 pm
Ishita Drugs & Industries Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 306 (-33.0% YoY | -2.6% QoQ) ■ EBITDA: 9.4 (-67.6% YoY | -31.8% QoQ) ■ EBITDA Margin (%): 3.1 (-329 bps YoY | -133 bps QoQ) ■ PAT: 17.7 (-38.4% YoY | +14.1% QoQ) ■ EPS (INR): 0.59 (-38.5% YoY | +13.5% QoQ)
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To consider, approve ....
Intimation · 30 May 2026, 5:30 am
Ishita Drugs Board Meeting on May 30th to Approve Q4 & FY26 Results Ishita Drugs & Industries (BSE: 524400) will hold a Board Meeting on Sat, 30th May'26, to consider and approve the audited financial results for the quarter and year ended 31st Mar'26. The agenda also includes approving the Directors' Report for the 33rd AGM and considering the re-appointment of internal auditors for FY26-27. The trading window for designated persons has been closed from 01st Apr'26 and will remain so until 48 hours after the results are announced.
The meeting of the Board of Directors of the Company will be held on Saturday, 30th May, 2026 to transact the following business: 1. To consider and take on records the Audited Financial ....
Intimation · 30 May 2026, 5:30 am
Ishita Drugs Board Meeting on May 30 to Approve Q4 & FY26 Results Ishita Drugs & Industries Ltd. (BSE: 524400) will hold a board meeting on 30th May'26 to consider and approve the audited financial results for the quarter and year ended 31st Mar'26. The agenda also includes approving the Directors' Report, considering the re-appointment of internal auditors for FY27, and convening the 33rd Annual General Meeting. The trading window for designated persons has been closed since 01st Apr'26 and will reopen 48 hours after the results are announced.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 28 Apr 2026, 8:09 pm
Ishita Drugs Confirms It Is Not a Large Corporate for FY26 Ishita Drugs & Industries Ltd. has formally notified the BSE that it does not meet the criteria to be classified as a "Large Corporate" as of 31st Mar'26. This assessment is based on SEBI circulars concerning fundraising via debt securities. Consequently, the company is exempt from the mandatory fundraising and disclosure requirements applicable to Large Corporates for the financial year 2025-26. The filing was dated 28th Apr'26.